Atty. Dkt. No. 034536-0920

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Malcolm Wilson MOON et al.

Title: Mannich Base Prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-Indolinone Derivatives

Appl. No.: Unassigned

Filing Date: 12/24/2003

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/863,804, filed 05/24/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language documents is explained in the parent application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date: December 24, 2003

By _____

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
(use as many sheets as necessary)				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	11	Attorney Docket Number	034536-0920

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	2968557		Burgandt et al.	01/1719/61	
	A2	4002749		Rovnyak	01/11/1977	
	A3	4053613		Rovnyak et al.	10/11/1977	
	A4	4642309		Michel et al.	02/10/1987	
	A5	4826847		Michel et al.	05/02/1989	
	A6	5051417		Nadler et al.	09/24/1991	
	A7	5124347		Connor et al.	06/23/1992	
	A8	5196446		Levitzki et al.	03/23/1993	
	A9	5302606		Spada et al.	04/12/1994	
	A10	5322950		Sircar et al.	06/21/1994	
	A11	5374652		Buzzetti et al.	12/20/1994	
	A12	5382593		Le Baut et al.	01/17/1995	
	A13	5389661		Sircar et al.	02/14/1995	
	A14	5397787		Buzzetti et al.	03/14/1995	
	A15	5409949		Buzzetti et al.	04/25/1995	
	A16	5792783		Tang et al.	08/11/1998	
	A17	5834504		Tang et al.	11/10/1998	
	A18	5849710		Battistini et al.	12/15/1998	
	A19	5880141		Tang et al.	03/9/1999	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	2	of	11	Attorney Docket Number	034536-0920

U.S. PATENT DOCUMENTS

		U.S. Patent Document				
	A20	5883113		Tang et al.	03/16/1999	
	A21	5883116		Tang et al.	03/16/1999	
	A22	5886020		Tang et al.	03/23/1999	
	A23	6133305		Tang et al.	10/17/2000	
	A24	6451838		Moon et al.	09/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Office[3]	Number[4]	Kind Code[5] (*if known*)				
	A25	WO	91/13055			09/05/1991		
	A26	WO	92/07830			05/14/1992		
	A27	WO	92/20642			11/26/1992		
	A28	WO	93/01182			01/21/1993		
	A29	WO	94/14808			07/07/1994		
	A30	WO	95/01349			01/12/1995		
	A31	WO	95/17181			06/29/1995		
	A32	WO	96/00226			01/04/1996		
	A33	WO	96/16964			06/06/1996		
	A34	WO	96/22976			08/01/1995		
	A35	WO	96/32380			10/17/1996		
	A36	WO	96/40116			12/19/1996		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
Date Submitted: December 24, 2003				**Filing Date**	12/24/2003
				First Named Inventor	Malcolm Wilson MOON
(use as many sheets as necessary)				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	11	Attorney Docket Number	034536-0920

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Office[3]	Number[4]	Kind Code[5] (*if known*)				
	A37	WO	97/25986			07/24/1997		
	A38	WO	98/07695			02/26/98		
	A39	WO	98/24432			6/11/98		
	A40	WO	98/38984			9/11/98		
	A41	WO	98/50356			11/12/98		
	A42	WO	99/10325			3/4/99		
	A43	WO	99/52869			10/21/99		
	A44	WO	99/61422			12/2/99		
	A45	WO	99/65869			12/23/99		
	A46	WO	00/08202			2/17/00		
	A47	WO	00/35906			6/22/00		
	A48	WO	00/35908			6/22/00		
	A49	WO	00/35909			6/22/00		
	A50	WO	00/38519			7/6/00		
	A51	WO	00/56709			9/28/00		
	A52	WO	01/60814			8/23/01		
	A53	WO	01//90104			11/29/01		
	A54	DE	2159360			11/30/71		Trans.
	A55	DE	2159361			11/30/71		Trans.

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	4	of	11	Attorney Docket Number	034536-0920

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A56	DE	2159362			11/30/71		
	A57	DE	2159363			11/29/71		Trans.
	A58	DE	2321656			4/28/73		Trans.
	A59	DE	3426419			1/23/86		Trans.
	A60	EP	0252713			9/12/1990		
	A61	EP	0351213			1/17/90		
	A62	EP	0525472			2/3/93		
	A63	EP	0632102			1/4/95		Trans.
	A64	EP	0662473			7/12/95		
	A65	EP	0788890			8/13/97		
	A66	EP	0769947			5/2/97		
	A67	EP	0934931			8/11/99		
	A68	EP	1082305	A1		3/14/01		
	A69	FR	1398224			3/29/65		Trans.
	A70	FR	1599772			8/1970		Trans.
	A71	FR	2689397			10/8/93		Trans.
	A72	FR	809691			3/4/59		
	A73	FR	835473			5/18/60		
	A74	JP	6229570			7/2/87		Trans.

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 24, 2003

(use as many sheets as necessary)

Sheet 5 of 11

Complete if Known	
Application Number	Unassigned
Filing Date	12/24/2003
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0920

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A75	JP	6239564			2/20/87		Trans.
	A76	JP	63141955			6/14/88		Trans.
	A77	JP	558894			3/9/93		Trans.
	A78	CA	2012634			9/20/91		
	A79	AU	286870			5/11/67		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A80	Andreani et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," Anticancer Research 16:3585-3588 (1996) 8 Elsevier, Paris	
	A81	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," Eur. J. Med. Chem. 25:187-190 (1990)	
	A82	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," Eur. J. Med. Chem. 28:653-657 (1993) 8 Elsevier, Paris	
	A83	Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," Eur. J. Med. Chem. 27:167-170 (1992) 8 Elsevier, Paris	
	A84	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," Eur. J. Med. Chem. 32:919-924 (1997)8 Elsevier, Paris	
	A85	Andreani et al., "Synthesis of lactams with potential cardiotonic activity," Eur. J. Med. Chem. 28:825-829 (1993)	
	A86	Andreani et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," Arzneimittel-Forschung Drug Research 48:727-729 (1998) 8	
	A87	Bahner and Brotherton, "9-(4-Aminobenzylidene)fluorenes," J. Med. Chem. 12:722-723 (1969)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	6	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A88	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," J. Med. Chem. 12:721-722 (1969)	
	A89	Bamfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," J. Chem. Soc. (C) 1028-1030 (1966) 8	
	A90	Borsche et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," Liebigs Ann. Chem. 550:160-174 (1941)	
	A91	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," Il Farmaco 48:615-636 (1993)	
	A92	Chatten et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted *trans*-3-Benzylideneindol-2(3*H*)-ones," J. Chem. Soc. Perkin II: 469-473 (1973)	
	A93	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," J. Chem. Soc. Perkin Trans. II: 615-619 (1984)	
	A94	Coda et al., "3-(4-methylbenzilidene)-1,3-dihydroindol-2-one," Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21	
	A95	Decodts et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," Eur. J. Med. Chem 18: 107-111 (1983)	
	A96	Desimoni et al., "Catalysis with Inorganic Cations. V[1] Intramolecular Hetero Diels-Alder *versus* Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity,"Tetrahedron 52(36) 12009-12018 (1196) 8 Pergamon	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	7	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A97	Elliott and Rivers, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," J. Med. Chem. 29:2438-2440 (1964)	
	A98	Elliott et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Journal of Organic Chemistry 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24	
	A99	Gazit et al., "Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," J. Med. Chem. 34:1896-1907 (1991) copyright Am. Clem. Soc.	
	A100	Hirao et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," Tetrahedron Letters 36(35) 1995 8Pergamon	
	A101	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," Canadian J. Chemistry 46:2189-2194 (1968)	
	A102	Howard, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134	
	A103	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1*H*)-benzimidazolone- and oxindole-1-acetic acids," Eur. J. Med. Chem. 27:779-789 (1992) 8 Elsevier, Paris	
	A104	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," J. Heterocyclic Chem. 25:1287-1292 (1988)	
	A105	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," Yakugaku Zasshi 97:1033-1039 (1977)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	8	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A106	Kovac and Stetinova, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles," Chem. rvesu 30:484-492 (1976)	
	A107	Levitzki and Gazit, "Tyrosine Kinase Inhibition: An Approach to Drug Development," Science 267:1782-1788 (1995)	
	A108	Mariani et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Experimental Therapeutics - Proceedings of the American Association for Cancer Research 35:381 at abstract no. 2268 (March 1994)	
	A109	Mohammadi et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," Science 276:955-960 (1997) 8 American Association for the Advancement of Science	
	A110	Neber and Röcker, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," Chem. Ber. 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)	
	A111	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," Chemical Abstracts, Vol. 83, abstract no. 188214 (1975)	
	A112	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," Clinica Chimica Acta 62:181-182 (1975) 8Elsevier Scientific Publishing Company	
	A113	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," Dopov. Akad. Nauk Ukr Rsrs, Ser. B: Geol., Khim. Biol. Nauki 7:64-66 (1980)	
	A114	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P 7:334-339 (1994)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	9	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A115	Quallich et al., Á General Oxindole Synthesis," J. Synthetic Organic Chemistry: 51-51 (1993)	
	A116	Schuchter et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," Cancer Research 51:682-687 (1991)	
	A117	Shiraishi et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," Biochemical and Biophysical Research Communications 147:322-328 (1987)8 Academic Press	
	A118	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives in Vitro," Cancer Research 49:2374-2378 (1989)	
	A119	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," Zentralbl. Mikrobiol. 144:105-109 (1989) copyright VEB Gustav Fischer Veriag Jena	
	A120	Spada, et al., "Small molecule inhibitors of tyrosine kinase activity," Expert Opinion on Therapeutic Patents 5:805-817 (1995) 8Ashley Publications	
	A121	Sun et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl) methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," Journal of Medicinal Chemistry 42: 5120-5130 (1999) 8American Chemical Society	
	A122	Sun et al, "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," J. Med. Chem. 41:2588-2603 (1998) 8The American Chemical Society	
	A123	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," Ricerca Scientifica 38:1239-1244 (1968)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	10	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A124	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," J.C.S. Perkin II 150-154 (1976)	
	A125	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," J. Chem. Soc. Perkin Trans. (I) 1835-1837 (1993)	
	A126	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," Expert Opinion on Therapeutic Patents 7(6):571-588 (1997) 8 Ashley Publications Ltd.	
	A127	Wahl et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," Ann. Chim. 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290	
	A128	Wahl, Beilstein Reg. No. 191439, Bull. Soc. Chim. Fr., page 1038 (1909)	
	A129	Wahl, Beilstein Reg. No. 231732, Bull. Soc. Chim. Fr., pages 1035-1038 (1909)	
	A130	Walker et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," J. Med. Chem. 8:626-637 (1965)	
	A131	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," J. Am. Chem. Soc. 78:221-224 (1956)	
	A132	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," J. Cellular Physiology 152:448-457 (1992)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Applicati n Number**	Unassigned
				Filing Date	12/24/2003
Date Submitted: December 24, 2003				**First Named Inventor**	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	11	of	11	Attorney Docket Number	034536-0920

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A133	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-234 (1996) copyright The American Society for Pharmacology and Experimental Pharmaceutics	
	A134	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," Chemical Abstracts, Vol. 78, abstract no. 111201 (1990)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.